Red Spruce Capital LLC Boosts Stake in Abbott Laboratories $ABT

Red Spruce Capital LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 24.3% in the second quarter, HoldingsChannel.com reports. The fund owned 36,210 shares of the healthcare product maker’s stock after acquiring an additional 7,078 shares during the quarter. Red Spruce Capital LLC’s holdings in Abbott Laboratories were worth $3,286,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Nia Impact Advisors LLC lifted its stake in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after purchasing an additional 79 shares during the last quarter. Riggs Asset Managment Co. Inc. raised its holdings in shares of Abbott Laboratories by 9.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after buying an additional 88 shares in the last quarter. GHP Investment Advisors Inc. raised its holdings in shares of Abbott Laboratories by 0.3% during the 4th quarter. GHP Investment Advisors Inc. now owns 29,411 shares of the healthcare product maker’s stock valued at $3,685,000 after buying an additional 92 shares in the last quarter. Eley Financial Management Inc lifted its position in Abbott Laboratories by 0.9% in the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock worth $1,355,000 after buying an additional 92 shares during the last quarter. Finally, Copley Financial Group Inc. boosted its stake in Abbott Laboratories by 2.1% in the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock worth $556,000 after buying an additional 93 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on ABT. Jefferies Financial Group decreased their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Citigroup boosted their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target for the company. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $118.17.

Abbott Laboratories Stock Up 2.0%

Shares of Abbott Laboratories stock opened at $107.86 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company’s 50 day moving average price is $95.06 and its 200-day moving average price is $99.97. The stock has a market capitalization of $186.63 billion, a price-to-earnings ratio of 34.90, a P/E/G ratio of 2.05 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm’s revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.